

Amendments to the Claims

- 1-38. (canceled)
39. (currently amended) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:
- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
 - (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
 - (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
 - (d) the nucleic acid sequence of (SEQ ID NO: 289);
 - (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
 - (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927;
- ~~— wherein the polypeptide encoded by said nucleic acid is an immunostimulant.~~
40. (currently amended) The isolated nucleic acid of Claim 39 having at least 85% nucleic acid sequence identity to:
- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
 - (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
 - (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
 - (d) the nucleic acid sequence of (SEQ ID NO: 289);
 - (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
 - (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927;
- ~~— wherein the polypeptide encoded by said nucleic acid is an immunostimulant.~~

41. (currently amended) The isolated nucleic acid of Claim 39 having at least 90% nucleic acid sequence identity to:
- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
 - (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
 - (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
 - (d) the nucleic acid sequence of (SEQ ID NO: 289);
 - (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
 - (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927;
- ~~— wherein the polypeptide encoded by said nucleic acid is an immunostimulant.~~

42. (currently amended) The isolated nucleic acid of Claim 39 having at least 95% nucleic acid sequence identity to:
- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
 - (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
 - (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
 - (d) the nucleic acid sequence of (SEQ ID NO: 289);
 - (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
 - (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927;
- ~~— wherein the polypeptide encoded by said nucleic acid is an immunostimulant.~~

43. (currently amended) The isolated nucleic acid of Claim 39 having at least 99% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927;

~~wherein the polypeptide encoded by said nucleic acid is an immunostimulant.~~

44. (previously presented) An isolated nucleic acid comprising:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927.

45. (previously presented) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290).

46. (previously presented) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide.

47. (previously presented) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290).

48. (cancelled)

49. (previously presented) The isolated nucleic acid of Claim 44 comprising the nucleic acid sequence of (SEQ ID NO: 289).

50. (previously presented) The isolated nucleic acid of Claim 44 comprising the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289).

51. (previously presented) The isolated nucleic acid of Claim 44 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209927.

52. (previously presented) An isolated nucleic acid molecule consisting of a fragment of the nucleic acid sequence of SEQ ID NO: 289, or a complement thereof, that specifically hybridizes under stringent conditions to:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein said stringent conditions are hybridization in 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

53–54. (cancelled)

55. (previously presented) A vector comprising the nucleic acid of Claim 39.

56. (previously presented) The vector of Claim 55, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

57. (previously presented) A host cell comprising the vector of Claim 55.

58. (previously presented) The host cell of Claim 57, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.